Well Referenced

Tag: Irritable Bowel Syndrome

American Gastroenterological Association Institute Guideline on the Pharmacological Management of Irritable Bowel Syndrome

This 2014 guideline by the American Gastroenterological Association (AGA) provides evidence-based recommendations for the pharmacological treatment of irritable bowel syndrome (IBS) in adults. Utilizing the GRADE methodology, the guideline evaluates various medications for IBS subtypes. For IBS with constipation (IBS-C), it recommends linaclotide and lubiprostone. For IBS with diarrhea (IBS-D),

Read More »
June 26, 2025 No Comments

A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome

This 2014 randomized, single-blind, crossover trial by Halmos et al. evaluated the effects of a low-FODMAP diet versus a typical Australian diet in 30 patients with IBS and 8 healthy controls. Participants followed each diet for 21 days. The low-FODMAP diet significantly reduced IBS symptoms, including bloating, abdominal pain, and

Read More »
June 26, 2025 No Comments

Intestinal microbiota in pathophysiology and management of irritable bowel syndrome

This 2014 review examines the role of intestinal microbiota in the pathophysiology and management of irritable bowel syndrome (IBS). It highlights that alterations in gut microbiota composition, known as dysbiosis, may contribute to IBS symptoms by affecting mucosal immunity, increasing epithelial permeability, and activating sensory-motor dysfunction. The review discusses potential

Read More »
June 26, 2025 No Comments

From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

This review highlights the utility of fecal calprotectin (FC) as a non-invasive biomarker for managing inflammatory bowel diseases (IBD). It describes FC’s role in differentiating IBD from irritable bowel syndrome (IBS), monitoring disease activity, predicting relapses, and evaluating treatment response. Although FC levels correlate well with mucosal healing and histology,

Read More »
June 26, 2025 No Comments

Fecal bacteria and short-chain fatty acids in irritable bowel syndrome: Relations to subtype

This observational study explored the associations between gut microbiota, short-chain fatty acid (SCFA) levels, and irritable bowel syndrome (IBS) subtypes and symptoms. IBS patients exhibited distinct microbial and SCFA profiles compared to healthy controls, with variations among IBS subtypes. Certain bacteria, such as Clostridia and Veillonella spp., were linked to

Read More »
June 26, 2025 No Comments

Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

The 2016 observational study titled “Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients With Diarrhea-Predominant Irritable Bowel Syndrome” (PMID: 25972430) examined the effect of glutamine on tight junction protein expression in IBS-D patients. Using colonic biopsy specimens from 12 patients, researchers incubated tissues with glutamine at

Read More »
June 26, 2025 No Comments

Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome

This 2014 observational study published in Journal of Gastroenterology (PMID: 24435814) examined links between gut permeability, immune markers, and symptom severity in patients with irritable bowel syndrome (IBS). Using lactulose/mannitol (L/M) ratios to assess permeability and IL-10 levels to gauge immune response, the study identified a subgroup of IBS patients

Read More »
June 26, 2025 No Comments

Development and Validation of Test for “Leaky Gut” Small Intestinal and Colonic Permeability Using Sugars in Healthy Adults

This 2021 randomized controlled trial published in Gastroenterology (PMID: 33865841) evaluated the accuracy and reproducibility of sugar probe testing to assess intestinal permeability in healthy adults and IBS-D patients. Researchers found that ^13C-mannitol, unlike ^12C-mannitol, served as a reliable marker for small intestinal permeability, with consistent results unaffected by age,

Read More »
June 26, 2025 No Comments

Recognizing the Leaky Gut as a Trans-diagnostic Target for Neuroimmune Disorders Using Clinical Chemistry and Molecular Immunology Assays

This 2018 systematic review published in Current Topics in Medicinal Chemistry (PMID: 30430944) examines the role of increased intestinal permeability—commonly referred to as leaky gut—in the development of neuroimmune disorders such as major depressive disorder (MDD), chronic fatigue syndrome (CFS), schizophrenia, and irritable bowel syndrome (IBS). The review highlights a

Read More »
June 26, 2025 No Comments